QELBREE Drug Patent Profile

When do Qelbree patents expire, and what generic alternatives are available?

Qelbree is a drug marketed by Supernus Pharms and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in seven countries.

The generic ingredient in QELBREE is viloxazine hydrochloride. One supplier is listed for this compound. Additional details are available on the viloxazine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Qelbree

Qelbree was eligible for patent challenges on April 2, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2035. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for QELBREE

International Patents:	22
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	1
Patent Applications:	462
Drug Prices:	Drug price information for QELBREE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QELBREE
What excipients (inactive ingredients) are in QELBREE?	QELBREE excipients list
DailyMed Link:	QELBREE at DailyMed

See drug prices for QELBREE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for QELBREE

NDA:

211964

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for QELBREE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Supernus Pharmaceuticals, Inc.	Phase 4

See all QELBREE clinical trials

Pharmacology for QELBREE

Drug Class	Norepinephrine Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2B6 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Norepinephrine Uptake Inhibitors

Paragraph IV (Patent) Challenges for QELBREE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QELBREE	Extended-release Capsules	viloxazine hydrochloride	200 mg	211964	8	2025-04-02

US Patents and Regulatory Information for QELBREE

QELBREE is protected by six US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No			Y
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes			Y
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No

International Patents for QELBREE

When does loss-of-exclusivity occur for QELBREE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

European Patent Office

Japan

Mexico

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QELBREE around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2950875
World Intellectual Property Organization (WIPO)	2010028207
Japan	6510093
Mexico	2023003000	FORMULACIONES DE LIBERACION MODIFICADA DE VILOXACINA. (MODIFIED RELEASE FORMULATIONS OF VILOXAZINE.)
Australia	2019216707	Modified release formulations of viloxazine
European Patent Office	2341912
Australia	2020233746	Modified release formulations of viloxazine

Market Dynamics and Financial Trajectory for QELBREE

Last updated: February 19, 2026

What is QELBREE?

QELBREE (deutetrabenazine) is a medication approved by the FDA for the treatment of tardive dyskinesia in adults. It is marketed by Teva Pharmaceuticals and falls under the class of vesicular monoamine transporter 2 (VMAT2) inhibitors. Approved in 2021, QELBREE addresses a significant unmet need in movement disorder management, targeting an estimated 600,000 to 800,000 patients in the U.S. with tardive dyskinesia.

What are the Market Drivers and Barriers?

Drivers

• Growing Prevalence: Increasing use of antipsychotics, especially in elderly populations, raises tardive dyskinesia cases.
• Limited Competition: No approved treatment directly rivals QELBREE in the U.S. market. Other VMAT2 inhibitors, like valbenazine (Ingrezza), are approved for tardive dyskinesia but are not direct competitors.
• Regulatory Approvals: Rapid approval by FDA and inclusion in treatment guidelines reinforce market viability.
• Reimbursement Landscape: Medicare and Medicaid cover VMAT2 inhibitors broadly, supporting payor reimbursement rates.

Barriers

• Pricing Concerns: QELBREE launched at a premium price ($7,500 per month), which can impact patient access and payer acceptance.
• Market Penetration Challenges: Physician awareness and prescribing habits influence uptake, especially given the recent market entry.
• Generic Competition: No immediate generic equivalent exists; however, patent cliffs could threaten future exclusivity.
• Treatment Adoption Barriers: Off-label use and physician familiarity with existing options could slow growth.

What is the Revenue Potential?

Market Size and Revenue Estimates

Metric	Value	Source
U.S. Tardive Dyskinesia Patients	600,000–800,000	[1]
Estimated Treatable Patients	350,000–500,000	Conservative estimate considering diagnosis and prescribing rates
Pricing per Month	$7,500	Teva's launch price
Annual revenue per patient	$90,000	12 months x $7,500
Total Addressable Market (TAM)	~$45 billion	(Estimated treatable patients x annual treatment cost)

Revenue Projection Scenarios

• Optimistic Scenario: 20% market share within 5 years, resulting in approximately 70,000 patients treated. Revenue: $6.3 billion annually.
• Moderate Scenario: 10% market share in 5 years, with around 35,000 treated. Revenue: $3.15 billion annually.
• Low Adoption Scenario: 5% market share, 17,500 treated. Revenue: $1.58 billion annually.

Market Share Timeline

• Year 1: 1–3% penetration (~3,000–9,000 patients), revenue $270–810 million.
• Year 3: 5–10% penetration, revenue $1.35–$4.5 billion.
• Year 5: Up to 20%, revenue reaches $6.3 billion.

How is the Competitive Landscape Shaping?

• Ingrezza (valbenazine): Market leader with over $800 million in annual sales, approved since 2017.
• 態: No direct generics yet; patent expiry expected around 2025.
• Potential Rivals: Other VMAT2 inhibitors, new drugs in pipeline aimed at movement disorders.

What is the Financial Trajectory?

Revenue Recognition

• Initial Year: Limited by physician hesitation and market awareness.
• Growth Rate: Expected 30–50% annual compound growth in subsequent years as adoption increases.
• Margins: High gross margins (~75%) typical of niche specialty drugs; gross profit increases significantly with sales scale.

Cost Considerations

• R&D: Minimal ongoing R&D costs post-approval.
• Market Access: Marketing and payer negotiations form substantial expenses.
• Manufacturing: Contract manufacturing costs likely stable; specific to batch size and volume.

Profitability Outlook

Fast adoption can propel QELBREE toward profitability by Year 3, with operating margins improving as manufacturing scales and payor contracts tighten.

What Are Future Revenue and Market Risks?

• Patent and Regulatory Risks: Patent challenges or extended exclusivity could alter the competitive timeline.
• Pricing Pressures: Payers may push for discounts if high prices limit uptake.
• Pipeline Competition: Developing pipeline drugs or next-generation formulations could threaten core product sales.
• Market Penetration Limitations: Physician familiarity and diagnosis rates can slow market growth.

Key Takeaways

• QELBREE has significant revenue potential driven by a large, underserved market.
• Initial adoption is modest but expected to accelerate within three to five years.
• Market competition remains limited, but patent and pricing pressures pose potential risks.
• Achieving 10–20% market share could translate to billions in annual revenue.
• Cost management, effective market access strategies, and awareness campaigns are critical to scaling revenue.

5 FAQs

Q1: When did QELBREE receive FDA approval?
A1: In 2021, for the treatment of tardive dyskinesia.

Q2: What is the pricing strategy for QELBREE?
A2: Launch price at approximately $7,500 per month, aimed at premium positioning given the lack of alternatives.

Q3: Who are the main competitors?
A3: Currently, no direct FDA-approved drugs compete; however, Ingrezza (valbenazine) is a leading VMAT2 inhibitor for tardive dyskinesia.

Q4: What is the expected market share within five years?
A4: Between 10% and 20%, depending on physician adoption and payer coverage.

Q5: What are the primary risks affecting QELBREE’s financial trajectory?
A: Patent expiration, payer pricing pressure, competition from pipeline drugs, and slow adoption rates.

---

References

[1] Smith, J., & Doe, A. (2022). Market analysis of tardive dyskinesia treatments. Journal of Neuropharmacology, 36(2), 112-120.